Abstract:Feng Yao, 1, &ast Chenguang Wang, 2, &ast Jie Ding, 1 Qian Zhang, 1 Liang Zheng, 1 Qin Zhang, 1 Tianshu Yang, 2 Xunmin Zhang, 2 Yong Shan, 2 Sheng Hou, 2 Hao Wang, 2 Renpeng Zhou, 1 Wei Hu 1 1 Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 2 Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Hu; Renpeng Zhou, Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui, 230601, People's Republic of China, Tel/Fax + 86 0551 65997164, Email ; Purpose: Secukinumab, a monoclonal antibody targeting interleukin (IL)-17A, is approved for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. This study compared the pharmacokinetics (PK), safety, and immunogenicity of CMAB015, a candidate secukinumab biosimilar, with the reference product secukinumab (Cosentyx ® ) in healthy Chinese male subjects. Patients and methods: This double-blind, parallel-group study randomized healthy Chinese male subjects (N=130) to receive either a single dose of 150 mg CMAB015 or secukinumab subcutaneously. Primary study endpoints were PK parameters such as the maximum concentration (C max ) and area under the curve from zero to infinity (AUC 0-inf ), while safety and immunogenicity were secondary endpoints. Results: The 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of C max and AUC 0-inf for CMAB015 to secukinumab were all within the bioequivalence limits (80.00– 125.00%). Other PK parameters were comparable between the groups. The safety profile of CMAB015 was similar to that of secukinumab, with no serious adverse events related to treatment. The incidence of TEAEs was slightly higher in the CMAB015 group, but these events were mild to moderate in severity and did not lead to any withdrawals from the study. Immunogenicity analysis revealed low rates of anti-drug antibody (ADA) positivity, with similar rates between CMAB015 and secukinumab. Conclusion: This study demonstrated equivalent PK, comparable safety, and immunogenicity of CMAB015 to secukinumab in healthy Chinese male subjects. These findings support further clinical evaluation of CMAB015 as a secukinumab biosimilar. Trial Registration: The trial was registered on Clinicaltrials.gov (Identifier No. NCT05734482) and Chinadrugtrials.org.cn (Identifier No. CTR20230105). Keywords: CMAB015, secukinumab, biosimilar, pharmacokinetics, safety, immunogenicity Interleukin-17A (IL-17A) is a pro-inflammatory cytokine belonging to the IL-17 family, known for its pivotal role in orchestrating inflammatory and immune responses. 1,2 Developed by Novartis, secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes IL-17A, thereby interrupting the inflammatory cascade driven by this cytokine. 3 The efficacy and safety of secukinumab have been well established in clinical trials, leading to its approval for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. 4–8 In particular, Phase III clinical trials have demonstrated the effectiveness of secukinumab in Chinese patients with moderate to severe plaque psoriasis, highlighting its potential as a valuable treatment option in this population. 9 Since its initial approval in Japan in December 2014, secukinumab has received regulatory approval in numerous countries, including the United States and the European Union, underscoring its global significance in the management of IL-17A-driven diseases. 10 The emergence of biosimilars offers a promising avenue for expanding access to effective biologic therapies while addressing cost considerations. A biosimilar is a biological product that is highly similar to an approved originator or reference product, with no clinically meaningful differences in safety, purity, or potency. 11 Biosimilars have the potential to increase treatment options for patients and healthcare providers, offering a more affordable alternative to costly biologic therapies. 12 The development and approval of biosimilars follow a well-regulated process in many countries. The European Medi -Abstract Truncated-

A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis

A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks

P1019 "Totality-of-the-evidence" of proposed ustekinumab biosimilar SB17"

P1081 Pharmacokinetics and immunogenicity of the ustekinumab biosimilar candidate ABP 654 in patients with moderate-to-severe plaque psoriasis

Pharmacokinetic Similarity of ABP 654, an Ustekinumab Biosimilar Candidate: Results from a Randomized, Double-blind Study in Healthy Subjects

New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects

P134 Characterization for the similarity assessment between proposed biosimilar SB17 and ustekinumab reference product using state-of-the-art analytical method

Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product

Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland

Efficacy And Safety Of Ustekinumab In Chinese Patients With Moderate To Severe Plaque-Type Psoriasis: Results From A Phase 3 Clinical Trial (Lotus)

A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects

Post‐Marketing Safety of Ustekinumab Based on 14‐Year Follow‐Up in Danish National Patient Data

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects

Bimekizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: a Meta-Analysis of Randomized Clinical Trials

A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials